Background: The National Institute for Health and Care Excellence recommends the use of generic
preference-based measures (GPBMs) of health for its Health Technology Assessments (HTAs). However,
these data may not be available or appropriate for all health conditions.
Objectives: To determine whether GPBMs are appropriate for some key conditions and to explore
alternative methods of utility estimation when data from GPBMs are unavailable or inappropriate.
Design: The project was conducted in three stages: (1) A systematic review of the psychometric properties
of three commonly used GPBMs [EQ-5D, SF-6D and Health Utilities Index Mark 3 (HUI3)] in four broadly
defined conditions: visual impairment, hearing impairment, cancer and skin conditions. (2) Potential
modelling approaches to ‘map’ EQ-5D values from condition-specific and clinical measures of health
[European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30
(EORTC QLQ-C30) and Functional Assessment of Cancer Therapy – General Scale (FACT-G)] are compared
for predictive ability and goodness of fit using two separate data sets. (3) Three potential extensions to the
EQ-5D are developed as ‘bolt-on’ items relating to hearing, tiredness and vision. They are valued using the
time trade-off method. A second valuation study is conducted to fully value the EQ-5D with and without
the vision bolt-on item in an additional sample of 300 people.
Setting: The valuation surveys were conducted using face-to-face interviews in the respondents’ homes.
Participants: Two representative samples of the UK general population from Yorkshire (n = 600).
Interventions: None.
Main outcome measures: Comparisons of EQ-5D, SF-6D and HUI3 in four conditions with various
generic and condition-specific measures. Mapping functions were estimated between EORTC QLQ-C30
and FACT-G with EQ-5D. Three bolt-ons to the EQ-5D were developed: EQ + hearing/vision/tiredness.
A full valuation study was conducted for the EQ + vision.
Results: (1) EQ-5D was valid and responsive for skin conditions and most cancers; in vision, its
performance varied according to aetiology; and performance was poor for hearing impairments. The HUI3
performed well for hearing and vision disorders. It also performed well in cancers although evidence was
limited and there was no evidence in skin conditions. There were limited data for SF-6D in all four
conditions and limited evidence on reliability of all instruments. (2) Mapping algorithms were estimated to
predict EQ-5D values from alternative cancer-specific measures of health. Response mapping using all the
domain scores was the best performing model for the EORTC QLQ-C30. In an exploratory analysis, a
limited dependent variable mixture model performed better than an equivalent linear model. In the full
analysis for the FACT-G, linear regression using ordinary least squares gave the best predictions followed
by the tobit model. (3) The exploratory valuation study found that bolt-on items for vision, hearing and
tiredness had a significant impact on values of the health states, but the direction and magnitude of
differences depended on the severity of the health state. The vision bolt-on item had a statistically
significant impact on EQ-5D health state values and a full valuation model was estimated.
Conclusions: EQ-5D performs well in studies of cancer and skin conditions. Mapping techniques
provide a solution to predict EQ-5D values where EQ-5D has not been administered. For conditions
where EQ-5D was found to be inappropriate, including some vision disorders and for hearing, bolt-ons
provide a promising solution. More primary research into the psychometric properties of the generic
preference-based measures is required, particularly in cancer and for the assessment of reliability.
Further research is needed for the development and valuation of bolt-ons to EQ-5D.
Funding: This project was funded by the UK Medical Research Council (MRC) as part of the MRC-NIHR
methodology research programme (reference G0901486) and will be published in full in Health Technology
Assessment; Vol. 18, No. 9. See the NIHR Journals Library website for further project information.

/pdf/use-of-generic-and-condition-specific-measures-of-health-45wf0us1gp.pdf

Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey

Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids.

This thesis employed methods used in health care decision making to evaluate strategies for prevention and treatment of febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients. The objectives of this thesis were to quantify the cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against FN in NHL patients, to develop an algorithm for converting health-related quality of life data collected in non-Hodgkin lymphoma patients into preference-based health utility values, and to evaluate NHL patients’ preferences for outpatient treatment of FN. The cost-effectiveness analysis demonstrated that neither filgrastim, nor pegfilgrastim are cost-effective, with respective incremental cost-effectiveness ratios [95% confidence interval] of $4,599,000/QALY [$597,045, dominated] and $6,272,000/QALY [$730,692, dominated], well above the normally accepted threshold of $50,000/QALY. The algorithm for deriving health utility values was based on a regression model that used health utility values obtained from the EQ-5D instrument as the outcome variable and the four subscales of the Functional Assessment of Cancer Therapy – General (FACT-G) questionnaire as the predictor variables. The model final model included three of the FACT-G subscales, and had an R-squared value of 0.502 and a mean squared error of 0.013. A discrete choice experiment

Lathi A Nina

Papers

Comprehensiveness of Quality of Life Instruments in Capturing Concerns Related to Chemotherapy-Induced Neutropenia